DiscoverKeeping CurrentShaping the Future: Expert Insights on Perioperative Immunotherapy for Gastric/GEJ Cancers
Shaping the Future: Expert Insights on Perioperative Immunotherapy for Gastric/GEJ Cancers

Shaping the Future: Expert Insights on Perioperative Immunotherapy for Gastric/GEJ Cancers

Update: 2025-09-23
Share

Description

Are you aware that programmed cell death-ligand 1 (PD-L1) testing may not be needed to guide immunotherapy decisions in resectable gastric/gastroesophageal junction (GEJ) cancers?
 
Credit available for this activity expires: 9/22/2026
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002919?ecd=bdc_podcast_libsyn_mscpedu

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Shaping the Future: Expert Insights on Perioperative Immunotherapy for Gastric/GEJ Cancers

Shaping the Future: Expert Insights on Perioperative Immunotherapy for Gastric/GEJ Cancers